2023
DOI: 10.14218/jerp.2022.00044
|View full text |Cite
|
Sign up to set email alerts
|

Ustekinumab in Dermatology: Approved Indications and Off-label Uses

Abstract: Ustekinumab is a human antibody that interacts with the p40 chain shared by both interleukin (IL)-12 and IL-23. Treatment with usterkinumab can effectively inactivate the biological functions of IL-12 and IL-23 to control aberrant Th1 and Th17 immunological responses. Ustekinumab is the first unique IL-12/IL-23 blocker approved by the Food and Drug Administration for the treatment of patients with moderate or severe psoriasis. Subsequently, its application has extended as a therapeutic option for psoriatic art… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 66 publications
0
0
0
Order By: Relevance